CyteQuest

Executive Summary

CyteQuest is a San Diego-based biotechnology company pioneering advanced microfluidic electroporation platforms for cell and gene therapy manufacturing. Founded in 2018, its core technology creates transient pores in cell membranes to deliver genetic cargo with high efficiency and superior cell viability, addressing a critical bottleneck in the production of cell and gene therapies. The company's continuous-flow system is designed to scale seamlessly from R&D to commercial production, potentially enabling manufacturers to reduce costs and improve yields. By focusing on scalability, process consistency, and cell health, CyteQuest differentiates itself from traditional batch electroporation methods that often suffer from low throughput and viability issues. The cell and gene therapy market is rapidly expanding, with growing demand for manufacturing solutions that can handle increasing patient volumes. CyteQuest's platform positions it to capture a significant share of this market, targeting partnerships with biopharma companies and contract development and manufacturing organizations (CDMOs). With its innovative approach and experienced team, the company is well-placed to become a key enabler in the production of next-generation therapies. However, as a private company with limited disclosure, execution risks and the need for further validation and capital remain key factors to monitor.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership Announcement with Leading Cell Therapy Developer70% success
• Q3 2026Successful Completion of Commercial-Scale Validation Study60% success
• Q2 2026Series B Funding Round Closing75% success